Midwest Allergy Sinus Asthma SC, Normal, IL. RATIONALE: Peanut allergy (PA) is increasing in prevalence and seriously impacts quality of life for patients and caregivers. To better understand the burden of PA, we explored allergic comorbidities reported in the PALISADE study population. METHODS: Study subjects were enrolled in PALISADE, a randomized, double-blind, placebo-controlled phase 3 trial of AR101 oral immunotherapy for PA. Eligible subjects were aged 4-55-years-old and tolerated < _100mg peanut protein as determined by a double-blind, placebocontrolled food challenge. Comorbidities calculated in the primary analysis population (4-17-years-old) included asthma (baseline asthma control test [ACT] and lung function also captured), atopic dermatitis (AD), allergic rhinitis (AR), other food allergies (FAs), and history of peanut-related anaphylaxis. RESULTS: 496 PA subjects aged 4-17-years-old enrolled in PALISADE (n5372 AR101-treated; n5124 placebo-treated). Median tolerated dose was 10mg peanut protein at baseline. Previous peanut-related anaphylaxis was reported in 72% (n5358) of subjects, with 30% of these experiencing > _2 episodes. 95% of subjects reported other atopic disorders or allergic comorbidities in addition to peanut allergy. 66% of subjects reported FAs in addition to peanut. Overall, AD was reported in 62% (n5308) of subjects and AR was reported in 72% (n5356). Approximately half of the population had asthma (53%, n5263) which was well-controlled (ACT score > _20) based on key inclusion/exclusion criteria. The distribution of these comorbidities was well-balanced between the AR101 and placebo groups. CONCLUSIONS: PALISADE enrolled a highly sensitive peanut-allergic cohort with multiple atopic comorbidities, presenting allergists the opportunity to continually evaluate and manage these common comorbid conditions associated with PA.
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Knowledge regarding epinephrine auto-injector use and peanut introduction among resident and staff pediatricians at an academic health center Andrea Aguilera, MD RATIONALE: Shellfish is a frequent cause of food allergy in AsiaPacific. Tropomyosin is recognized to be the major shrimp allergen. However, little is known about the prevalence of shrimp allergen sensitization among the Chinese population. This study aimed to evaluate the IgE sensitization pattern to shrimp allergens among shellfish-allergic patients in Hong Kong. METHODS: Chinese subjects with a history of shellfish allergy within five years and/or a positive skin prick test (wheal > _ 3 mm) to shellfish mixture were recruited. Serum specific IgE (sIgE) levels to shrimp extract and tropomyosin rPen a1 were measured by ImmunoCAP. sIgE reactivity to seven recombinant shrimp allergens including tropomyosin (TM), arginine kinase (AK), myosin light chain (MLC), sarcoplasmic calcium-binding protein (SCP), troponin C (TnC), triosephosphate isomerase (TIM) and fatty-acid-binding protein (FABP) were measured by ELISA. RESULTS: Among 74 shellfish-allergic subjects (54% male; median age 5 25 years [2-58]), 38 (51.4%) and 16 (21.6%) had positive sIgE (> _ 0.35 kU A /L) to shrimp extract and rPen a1, respectively. Sensitization to multiple shrimp allergens was common among subjects with positive sIgE to shrimp (17/38; 44.7%). Patients who were sensitized to shrimp by sIgE more frequently recognized TnC (19/38; 50.0%), followed by TM (16/ 38; 42.1%), and AK and FABP (15/38; 39.5%). CONCLUSIONS: Sensitization to multiple shrimp allergens was common in Chinese shellfish-allergic subjects, with TnC being the major allergen. Further studies need to examine the relationship between IgE sensitization pattern and clinical reactivity to shrimp. (Funding: Hong Kong Institute of Allergy Research Grant 2017; AXA Post-doctoral Fellowship)
